Sun Pharma shares dip on surprise audit by FDA at Halol plant

Shares of Sun Pharmaceutical Industries on Thursday fell by over 4% amid reports that its Halol manufacturing plant in Gujarat has been subjected to surprise inspection by the American drug regulator United States Food and Drug Administration (USFDA).

Shares of Sun Pharmaceutical Industries on Thursday fell by over 4% amid reports that its Halol manufacturing plant in Gujarat has been subjected to surprise inspection by the American drug regulator United States Food and Drug Administration (USFDA).

The pharma firm's scrip ended at Rs 822.80, down 4.29% on the BSE. During the day, it fell by 6% to Rs 808.

At the NSE, the stock lost 4.29% to Rs 821.

The stock was the biggest loser among the blue-chips on both Sensex and Nifty.

Sarabjit Kour Nangra, VP- Research (Pharma), Angel Broking said it is learnt that Sun Pharma's manufacturing facility in Halol (Gujarat) is undergoing a surprise inspection by the US Food and Drug Administration (US FDA).

The move may have been triggered by a number of recent recalls from the plant, sources, familiar with the development."

In the broader market the BSE benchmark Sensex ended at 26,995.87, down 61.54 points.